Report cover image

Italy Radiopharmaceuticals Market By Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic), By End User (Hospitals and clinics, Medical Imaging centers, Oth

Publisher Allied Market Research
Published May 02, 2023
Length 74 Pages
SKU # ALMR18790519

Description

Italy Radiopharmaceuticals Market By Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic), By End User (Hospitals and clinics, Medical Imaging centers, Others): Opportunity Analysis and Industry Forecast, 2023-2032


The radiopharmaceuticals market in Italy is growing progressively due to the rising demand for radiopharmaceuticals for diagnostics, rehabs, and research study tasks. Radiopharmaceuticals are contaminated medicines that are used in nuclear medication imaging. The market in Italy is driven by factors such as increasing incidence of cancer, rising investment in nuclear medicine, and also increasing technical developments. The rising aging population, increasing awareness, and federal government efforts to support nuclear medication are expected to create significant growth opportunities in the market in the upcoming years.

The increasing demand for radiopharmaceuticals in the diagnosis and treatment of illness, particularly cancer, is the major factor driving the Italy radiopharmaceutical market growth. The rising financial investment in nuclear medication and growing technical developments are also expected to contribute to the growth of the market in the upcoming years. The availability of advanced imaging modern technologies, government efforts, as well as the rising awareness concerning nuclear medication are some of the drivers of this market growth.

One of the major factors restraining the Italy radiopharmaceuticals market growth include the high expense related to the manufacturing of radiopharmaceuticals. In addition, the restricted accessibility of radiopharmaceuticals in some of the areas in the country, the need for continuous regulatory authorizations for the manufacture and supply of these products, as well as the requirement for specialized personnel who are appropriately educated and qualified to handle these products are some of the other factors hampering the market growth.

The increasing senior citizen population and the rising demand for radiopharmaceuticals for research activities are expected to create several growth opportunities for the radiopharmaceuticals market players in Italy. The rising emphasis on the R&D of radiopharmaceuticals, particularly for cancer treatment, is expected to boost the development of this market in the upcoming years.

The radiopharmaceuticals market in Italy is experiencing a number of new developments, including the introduction of advanced imaging modern technologies such as positron emission tomography (PET) as well as single-photon exhaust computed tomography (SPECT). These technologies are allowing doctors to get images of better quality and precision, and further driving the growth of the radiopharmaceuticals market in Italy. The increasing demand for radiopharmaceuticals in the diagnosis and therapy of cardiovascular diseases is also contributing to the growth of the radiopharmaceuticals market.

The increasing focus on the development of unique radiopharmaceuticals, such as Technetium-99m, Fluorine-18, and Iodine-131, is also one of the significant factors driving the radiopharmaceuticals market growth in Italy. This is mainly due to their fairly low-cost and longer shelf-life, that makes them ideal for usage in medical imaging. Furthermore, the rising use gallium-68-labeled radiopharmaceuticals for imaging the prostate gland is predicted to create several growth opportunities for the key players operating in the market in the upcoming years.

The Italy radiopharmaceuticals market is witnessing a number of new product developments. Business are investing greatly in R&D tasks to create cutting-edge as well as economical products. For instance, pharmaceutical business are working together with universities, research study institutes, and governments to establish products in this field. In addition, business are additionally increasing their profile of radiopharmaceutical products by acquiring local players in the market.

Major players operating in the Italy radiopharmaceuticals market are studied to understand their position and competitive strengths. The study profiles 10 major companies along with their brief overview, recent financials, main executives, adoption of key growth strategies, and novel advancements or initiatives to sustain & expand their position in the global Italy radiopharmaceuticals market.

The pricing techniques adopted by business in this market likewise differ substantially, depending on the type of product and the region. For instance, the costs of diagnostic radiopharmaceuticals are usually higher in bigger cities, compared to rural areas, due to their higher demand. Likewise, the prices of restorative radiopharmaceuticals in the Italy market are likewise substantially more than the worldwide standard, owing to higher production expenses and rigid regulations.

In order to acquire a competitive edge in the Italy radiopharmaceuticals market, players in this market need to adopt a detailed set of techniques. Firms need to concentrate on obtaining local gamers in order to broaden their product portfolio and also acquire a larger share of the market. Also, market advancement activities should likewise be carried out in order to reach out to prospective consumers in untapped regions.

R&D tasks must be encouraged in order to continue to be at the leading edge of the sector. Companies need to create inventive products that are of high quality and cost-efficient. Also, to acquire much better presence, companies need to concentrate on digital advertising and marketing campaigns.

Key Benefits For Stakeholders

Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
Analyze the key strategies adopted by major market players in the Italy radiopharmaceuticals market.
Assess and rank the top factors that are expected to affect the growth of the Italy radiopharmaceuticals market.
Top player positioning provides a clear understanding of the present position of market players.
Detailed analysis of the Italy radiopharmaceuticals market segmentation assists to determine prevailing market opportunities.

Identify key investment pockets for various offerings in the market
New Product Development/ Product Matrix of Key Players
Patient/epidemiology data at country, region, global level
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)
SWOT Analysis

Key Market Segments

By Type

Diagnostic
Therapeutic

By End User

Hospitals and clinics
Medical Imaging centers
Others

By Radioisotope

Fluorine 18
Iodine I
Gallium 68
Others
Technetium 99m

By Application

Cancer
Cardiology
Others

Key Market Players

Bracco Imaging
BBraun
IBA Molecular
TriRadiopharma
Eurotope
Mallinckrodt
Piramal Imaging
Jubilant DraxImage
Alseres Pharmaceuticals
Curium Pharma.

Please Note: It will take 7-10 business days to complete the report upon order confirmation. 

Table of Contents

74 Pages
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits to the Stakeholders
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Impacting Factors
3.2.2. Top Investment Pockets
3.3. Porter’s Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: ITALY RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
4.1. Overview
4.1.1. Market Size and Forecast, By Radioisotope
4.2. Technetium 99m
4.3. Fluorine 18
4.4. Iodine I
4.5. Gallium 68
4.6. Others
CHAPTER 5: ITALY RADIOPHARMACEUTICALS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market Size and Forecast, By Application
5.2. Cancer
5.3. Cardiology
5.4. Others
CHAPTER 6: ITALY RADIOPHARMACEUTICALS MARKET, BY TYPE
6.1. Overview
6.1.1. Market Size and Forecast, By Type
6.2. Diagnostic
6.3. Therapeutic
CHAPTER 7: ITALY RADIOPHARMACEUTICALS MARKET, BY END USER
7.1. Overview
7.1.1. Market Size and Forecast, By End User
7.2. Hospitals and clinics
7.3. Medical Imaging centers
7.4. Others
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Company 1
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Company 2
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Company 3
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Company 4
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Company 5
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Company 6
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Company 7
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Company 8
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Company 9
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Company 10
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. ITALY RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 02. ITALY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 03. ITALY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 04. ITALY RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 05. COMPANY 1: KEY EXECUTIVES
TABLE 06. COMPANY 1: COMPANY SNAPSHOT
TABLE 07. COMPANY 1: OPERATING SEGMENTS
TABLE 08. COMPANY 1: PRODUCT PORTFOLIO
TABLE 09. COMPANY 1: KEY STRATERGIES
TABLE 10. COMPANY 2: KEY EXECUTIVES
TABLE 11. COMPANY 2: COMPANY SNAPSHOT
TABLE 12. COMPANY 2: OPERATING SEGMENTS
TABLE 13. COMPANY 2: PRODUCT PORTFOLIO
TABLE 14. COMPANY 2: KEY STRATERGIES
TABLE 15. COMPANY 3: KEY EXECUTIVES
TABLE 16. COMPANY 3: COMPANY SNAPSHOT
TABLE 17. COMPANY 3: OPERATING SEGMENTS
TABLE 18. COMPANY 3: PRODUCT PORTFOLIO
TABLE 19. COMPANY 3: KEY STRATERGIES
TABLE 20. COMPANY 4: KEY EXECUTIVES
TABLE 21. COMPANY 4: COMPANY SNAPSHOT
TABLE 22. COMPANY 4: OPERATING SEGMENTS
TABLE 23. COMPANY 4: PRODUCT PORTFOLIO
TABLE 24. COMPANY 4: KEY STRATERGIES
TABLE 25. COMPANY 5: KEY EXECUTIVES
TABLE 26. COMPANY 5: COMPANY SNAPSHOT
TABLE 27. COMPANY 5: OPERATING SEGMENTS
TABLE 28. COMPANY 5: PRODUCT PORTFOLIO
TABLE 29. COMPANY 5: KEY STRATERGIES
TABLE 30. COMPANY 6: KEY EXECUTIVES
TABLE 31. COMPANY 6: COMPANY SNAPSHOT
TABLE 32. COMPANY 6: OPERATING SEGMENTS
TABLE 33. COMPANY 6: PRODUCT PORTFOLIO
TABLE 34. COMPANY 6: KEY STRATERGIES
TABLE 35. COMPANY 7: KEY EXECUTIVES
TABLE 36. COMPANY 7: COMPANY SNAPSHOT
TABLE 37. COMPANY 7: OPERATING SEGMENTS
TABLE 38. COMPANY 7: PRODUCT PORTFOLIO
TABLE 39. COMPANY 7: KEY STRATERGIES
TABLE 40. COMPANY 8: KEY EXECUTIVES
TABLE 41. COMPANY 8: COMPANY SNAPSHOT
TABLE 42. COMPANY 8: OPERATING SEGMENTS
TABLE 43. COMPANY 8: PRODUCT PORTFOLIO
TABLE 44. COMPANY 8: KEY STRATERGIES
TABLE 45. COMPANY 9: KEY EXECUTIVES
TABLE 46. COMPANY 9: COMPANY SNAPSHOT
TABLE 47. COMPANY 9: OPERATING SEGMENTS
TABLE 48. COMPANY 9: PRODUCT PORTFOLIO
TABLE 49. COMPANY 9: KEY STRATERGIES
TABLE 50. COMPANY 10: KEY EXECUTIVES
TABLE 51. COMPANY 10: COMPANY SNAPSHOT
TABLE 52. COMPANY 10: OPERATING SEGMENTS
TABLE 53. COMPANY 10: PRODUCT PORTFOLIO
TABLE 54. COMPANY 10: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. ITALY RADIOPHARMACEUTICALS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF ITALY RADIOPHARMACEUTICALS MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN ITALY RADIOPHARMACEUTICALS MARKET (2023-2032)
FIGURE 04. PORTER FIVE-1
FIGURE 05. PORTER FIVE-2
FIGURE 06. PORTER FIVE-3
FIGURE 07. PORTER FIVE-4
FIGURE 08. PORTER FIVE-5
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: ITALY RADIOPHARMACEUTICALS MARKET
FIGURE 10. ITALY RADIOPHARMACEUTICALS MARKET,BY RADIOISOTOPE, 2022 ($MILLION)
FIGURE 11. ITALY RADIOPHARMACEUTICALS MARKET,BY APPLICATION, 2022 ($MILLION)
FIGURE 12. ITALY RADIOPHARMACEUTICALS MARKET,BY TYPE, 2022 ($MILLION)
FIGURE 13. ITALY RADIOPHARMACEUTICALS MARKET,BY END USER, 2022 ($MILLION)
FIGURE 14. TOP WINNING STRATEGIES, BY YEAR
FIGURE 15. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 16. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 17. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 18. COMPETITIVE DASHBOARD
FIGURE 19. COMPETITIVE HEATMAP: ITALY RADIOPHARMACEUTICALS MARKET
FIGURE 20. TOP PLAYER POSITIONING, 2022
FIGURE 21. COMPANY 1: NET SALES, 2020-2022* ($MILLION)
FIGURE 22. COMPANY 1: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 23. COMPANY 1: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 24. COMPANY 2: NET SALES, 2020-2022* ($MILLION)
FIGURE 25. COMPANY 2: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 26. COMPANY 2: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 27. COMPANY 3: NET SALES, 2020-2022* ($MILLION)
FIGURE 28. COMPANY 3: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 29. COMPANY 3: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 30. COMPANY 4: NET SALES, 2020-2022* ($MILLION)
FIGURE 31. COMPANY 4: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 32. COMPANY 4: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 33. COMPANY 5: NET SALES, 2020-2022* ($MILLION)
FIGURE 34. COMPANY 5: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 35. COMPANY 5: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 36. COMPANY 6: NET SALES, 2020-2022* ($MILLION)
FIGURE 37. COMPANY 6: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 38. COMPANY 6: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 39. COMPANY 7: NET SALES, 2020-2022* ($MILLION)
FIGURE 40. COMPANY 7: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 41. COMPANY 7: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 42. COMPANY 8: NET SALES, 2020-2022* ($MILLION)
FIGURE 43. COMPANY 8: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 44. COMPANY 8: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 45. COMPANY 9: NET SALES, 2020-2022* ($MILLION)
FIGURE 46. COMPANY 9: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 47. COMPANY 9: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 48. COMPANY 10: NET SALES, 2020-2022* ($MILLION)
FIGURE 49. COMPANY 10: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 50. COMPANY 10: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us